AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Neurocrine’s Crenessity is an oral corticotropin-releasing factor type 1 receptor antagonist. Credit: Piotr Swat/Shutterstock. Neurocrine Biosciences has presented new one-year data from its Phase III ...